Birt-Hogg-Dubé (BHD) syndrome is associated with the development of hereditary renal cell carcinoma (RCC) and is caused by a germline mutation in the folliculin gene.
| INTRODUC TI ON
Hereditary cancer syndromes predispose patients and affected family members to multifocal and metachronous tumors. As genomic research has improved our understanding of the pathogenic events in each patient, hereditary cancers constitute an area of highly unmet medical needs. Comprehensive genomic approaches have increased the ability to identify hereditary cancers. As the carcinogenic mechanisms of hereditary cancers are now understood, therapeutic strategies to target the signaling cascades affected by the responsible genes have improved. As individuals with hereditary cancers potentially develop multifocal and metachronous disorders, it is important to preserve the functions of the affected organ(s) when the cancer is low grade.
The kidney is an essential organ for maintaining body fluid, electrolyte balance, blood pressure and hormone secretion. Although most cases of renal cell carcinoma (RCC) are sporadic, increasing numbers of previously undiagnosed hereditary cancers have been re-evaluated. 1 Birt-Hogg-Dubé (BHD) syndrome-associated RCC (BHD-RCC) is a newly emerging hereditary cancer whose genomic features and renal pathology have been evaluated intensively over the 20 years. We collected clinicopathological information from 220 independent Japanese families with BHD syndrome through consultation with the Japanese Society of Pathology (http://patho logy. or.jp/) and BHD-NET Japan (http://www.bhd-net.jp/). In this review, we summarize the histopathology of BHD-RCC based on data from these Japanese families. The diagnostic conundrum and differential diagnosis of BHD-RCC from other hereditary RCC are also discussed. Birt 
| B IRT-HOGG -DUB É SYNDROME G ENER AL INFORMATION

| CLINIC AL FE ATURE S OF B HD -RCC
Clinical information related to BHD syndrome has been collected and reviewed by several study groups, including the European BHD Consortium and National Cancer Institute (NCI) in the USA. 7, 8 Most Caucasians with BHD syndrome (85%-90%) have skin papules as the major complaint, whereas the incidence of pneumothorax is less frequent (24%). 9 In contrast, skin manifestations are not the major complaint in the Japanese population. 10 The fibrous papules in Japanese patients are generally subtle or non-detectable; therefore, skin manifestations alone are unlikely to raise suspicion of BHD syndrome in Japanese individuals unless other disorders such as pneumothorax or RCC are present. Physicians should consider the race-associated differences in the frequency of pneumothorax and conspicuity of skin papules. Renal carcinogenesis seems to be related to age, and the median age at RCC diagnosis in BHD patients is 46-56 years. 8, 10, 11 The morbidity rate of RCC in Caucasian populations is 27%-34% according to an NCI study. 12 
| HIS TOPATHOLOG IC AL FE ATURE S OF B HD -RCC
In 2002, for the first time, Pavlovich et al 13 HOCT and chromophobe BHD-RCC are a more yellowish color under formalin-fixed tissue conditions ( Figure 1C ). Central degeneration is occasionally observed, but necrosis is rare. The tumor may have a radial scar, which is otherwise common in sporadic oncocytomas. We experienced an unusual nodular scar that seemed to be an obsolete
RCC.
According to the World Health Organization (WHO) classification, HOCT is currently defined as a subtype of chromophobe RCC, which is a malignant neoplasm. HOCT is described as having an "overlapping histology between oncocytoma and chromophobe RCC" (Figure 1D Hybrid oncocytic/chromophobe tumors can occur in patients without BHD syndrome, which is known as sporadic HOCT (SHOCT). A recent study of 25 patients with SHOCT showed that six patients developed multifocal lesions (24%), two of whom had poor prognoses. 17 The differential diagnosis between BHD syn- derived from proximal tubules in patients with BHD syndrome, as discussed later.
| C Y TOG ENE TI C FE ATURE S OF B HD -RCC
A pioneering cytogenetic analysis showed distinctive gene expression patterns in BHD-RCC such as high expression of parvalbumin, a distal convoluted tubule marker. 19 The expression patterns in BHD-RCC are more similar to those of sporadic chromophobe RCC and oncocytoma than those of other RCC types which supports the immunostaining pattern. Gene expression profiling of BHD-RCC showed that HOCT and chromophobe RCC lack the mutations in driver genes (TP53, CDKN1A, RB1, PTEN and MTOR) that characterize sporadic chromophobe RCC. 20 No copy number variations were observed among chromosomes in any of the HOCT or chromophobe RCC cases, except for two chromophobe RCC cases with a 3q gain. 20, 21 These findings highlight a distinct difference between these BHD-RCC types and sporadic chromophobe RCC (classic type), which are characterized by copy number losses in chromosomes 1, 2, 6, 8, 10, 13, 17 and 21. 20, 22 HOCT and chromophobe BHD-RCC show a disomic pattern on FISH using probes targeting the centromeric regions of chromosomes 2, 6 and 17, whereas sporadic chromophobe RCC show a predominantly monosomic pattern. 23 Sporadic oncocytomas occasionally show copy number losses in chromosomes 1 and Y, as well as ERCC2 and C2CD4C mutations. 24, 25 A recent study showed that SHOCT also have copy number losses in chromosomes 1 and X/Y but lack recurrent mutations. 17 Collective cytogenetic studies have improved our understanding of the unique features of BHD-RCC but have also shown a limitation in the histology-based differential diagnosis of BHD-RCC from its sporadic counterparts. Our clear cell BHD-RCC cases (n = 2) showed no copy number alterations at 3p with wild-type von Hippel-Lindau tumor suppressor gene (VHL), 21 which is different from its sporadic counterparts, characterized by 3p copy number loss and VHL mutations. 26 However, the study by Pavlovich et al 13 According to epidemiological studies, 19.2%-45% of affected individuals develop renal cysts. 10, 27 Most renal cysts are benign, but tumors may develop within the cyst walls (Figure 2A,B) . We experienced four dialysis patients who developed multifocal tumors in 
| D IFFERENTIATI ON OF B DH -RCC FROM OTHER HERED ITARY RENAL NEOPL A S MS
The differential diagnosis of BDH-RCC is discussed in relation to tuberous sclerosis complex (TSC); hereditary leiomyomatosis and renal cell cancer (HLRCC); and succinate dehydrogenase (SDH)-deficient RCC.
Patients with TSC harbor germline mutations in either TSC1 or TSC2. TSC1, TSC2 and FLCN all mediate mTOR pathway signaling, although their functions and interaction partners are different. 29 TSC and BHD syndrome commonly affect the skin, lung and kidney.
Approximately two-thirds of TSC cases are the result of de novo comparisons of the lung cysts between the two disorders have been discussed in several reports. [33] [34] [35] In the kidney, angiomyolipoma is the most frequent neoplasm in TSC, developing in up to 80% of affected individuals, 36 and is composed of three cell types: vascular; adipose;
and smooth muscle cells. HMB45 is an immunohistochemical marker of angiomyolipomas. 37 Angiomyolipomas are benign in most TSC cases; however, they tend to increase in number and size and replace the renal parenchyma, leading to life-threatening hemorrhage. 38 Hereditary leiomyomatosis and renal cell cancer, also known as Figure 3D ).
The RCC component of HLRCC, in most cases, is highly aggressive and life-threatening. 29, 43 In addition, young adults and children occasionally develop RCC. 44 The histology of HLRCC-associated RCC was initially thought to be type 2 papillary architecture ( Figure 3E ), but later studies showed that these tumors occasionally show a mixture of solid, sieve-like, tubular, cystic and papillary components. 45 The morphological similarities between HLRCC-associated RCC and other RCC types such as collecting duct, tubulocystic and renal medullary carcinomas have been re-evaluated. 46 Rarely, a low-grade oncocytic morphology may be observed in HLRCC-associated RCC that is reminiscent of SDH-deficient RCC 47 (Figure 3F,G) . Individuals with germline mutations in the SDHB gene are at risk of developing SDH-deficient RCC. 48 Although the prognosis of SDH-deficient RCC is not fully understood, this RCC type is regarded as low-grade. 47 FH and SDH subunits (SDHA-D) are enzymes involved in the tricarboxylic acid cycle, and play important roles in the production of ATP. 29 Therefore, the hypothesis that HLRCC-associated RCC with an SDH-deficient RCC-like morphology has a more favorable course than that of HLRCC-associated RCC with a high-grade morphology requires further investigation. Immunohistochemically, HLRCCassociated RCC is generally negative for FH and diffusely positive for 2-succino cysteine. 49 It should be noted that FH-deficient RCC are not always associated with HLRCC. 50
| CON CLUS ION
We suggest that BHD-RCC, which consists of more than one histological type and shows unique cytogenetic features, may be defined more appropriately as an independent category rather than as a subtype of chromophobe RCC in the WHO classification.
Reclassification of some other rare RCC, such as hereditary and sporadic FH-deficient RCC, should be considered in the future.
However, genetic counseling and testing for hereditary RCC are not covered by government subsidies in Japan. In addition, genetic discrimination may be a concern among suspected individuals. Medical circumstances occasionally discourage patients from receiving genetic testing, which prevents them from receiving the correct diagnosis from medical geneticists and pathologists and evidence-based treatment from urologists. Legal protection of genetic information, such as the Genetic Information Nondiscrimination Act in the USA, should also be provisioned in Japan. Improvement of medical care for hereditary RCC patients and potential mutation carriers will be critical for their diagnosis and appropriate treatment.
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